145 related articles for article (PubMed ID: 32360240)
1. Risk of dementia in prostate cancer survivors: A nationwide cohort study in Korea.
Kang J; Shin DW; Han K; Park SH; Lee WG; Yoo JE; Woo SH; Park J
Curr Probl Cancer; 2020 Dec; 44(6):100578. PubMed ID: 32360240
[TBL] [Abstract][Full Text] [Related]
2. Risk of fracture incidence in prostate cancer survivors: a nationwide cohort study in South Korea.
Shin HB; Park HS; Yoo JE; Han K; Park SH; Shin DW; Park J
Arch Osteoporos; 2020 Jul; 15(1):110. PubMed ID: 32700143
[TBL] [Abstract][Full Text] [Related]
3. Risk of Ischemic Heart Disease and Stroke in Prostate Cancer Survivors: A Nationwide Study in South Korea.
Shin DW; Han K; Park HS; Lee SP; Park SH; Park J
Sci Rep; 2020 Jun; 10(1):10313. PubMed ID: 32587285
[TBL] [Abstract][Full Text] [Related]
4. Is androgen deprivation therapy associated with cerebral infarction in patients with prostate cancer? A Korean nationwide population-based propensity score matching study.
Tae BS; Jeon BJ; Choi H; Bae JH; Park JY
Cancer Med; 2019 Aug; 8(9):4475-4483. PubMed ID: 31183968
[TBL] [Abstract][Full Text] [Related]
5. Correlation of Androgen Deprivation Therapy with Cognitive Dysfunction in Patients with Prostate Cancer: A Nationwide Population-Based Study Using the National Health Insurance Service Database.
Tae BS; Jeon BJ; Shin SH; Choi H; Bae JH; Park JY
Cancer Res Treat; 2019 Apr; 51(2):593-602. PubMed ID: 30025445
[TBL] [Abstract][Full Text] [Related]
6. No increased risk of dementia in patients receiving androgen deprivation therapy for prostate cancer: a 5-year follow-up study.
Kao LT; Lin HC; Chung SD; Huang CY
Asian J Androl; 2017; 19(4):414-417. PubMed ID: 27232853
[TBL] [Abstract][Full Text] [Related]
7. Androgen deprivation therapy for prostate cancer and risk of dementia.
Robinson D; Garmo H; Van Hemelrijck M; Damber JE; Bratt O; Holmberg L; Wahlund LO; Stattin P; Adolfsson J
BJU Int; 2019 Jul; 124(1):87-92. PubMed ID: 30637900
[TBL] [Abstract][Full Text] [Related]
8. Association Between Androgen Deprivation Therapy and Risk of Dementia.
Nead KT; Gaskin G; Chester C; Swisher-McClure S; Leeper NJ; Shah NH
JAMA Oncol; 2017 Jan; 3(1):49-55. PubMed ID: 27737437
[TBL] [Abstract][Full Text] [Related]
9. Does androgen-deprivation therapy increase the risk of ischemic cardiovascular and cerebrovascular diseases in patients with prostate cancer? A nationwide population-based cohort study.
Kim DK; Lee HS; Park JY; Kim JW; Ha JS; Kim JH; Yang WJ; Cho KS
J Cancer Res Clin Oncol; 2021 Apr; 147(4):1217-1226. PubMed ID: 33000338
[TBL] [Abstract][Full Text] [Related]
10. Risks of Major Long-Term Side Effects Associated with Androgen-Deprivation Therapy in Men with Prostate Cancer.
Nguyen C; Lairson DR; Swartz MD; Du XL
Pharmacotherapy; 2018 Oct; 38(10):999-1009. PubMed ID: 30080934
[TBL] [Abstract][Full Text] [Related]
11. Type of Androgen Deprivation Therapy and Risk of Dementia Among Patients With Prostate Cancer in Taiwan.
Huang WK; Liu CH; Pang ST; Liu JR; Chang JW; Liaw CC; Hsu CL; Lin YC; See LC
JAMA Netw Open; 2020 Aug; 3(8):e2015189. PubMed ID: 32865575
[TBL] [Abstract][Full Text] [Related]
12. Association Between Androgen Deprivation Therapy Use and Diagnosis of Dementia in Men With Prostate Cancer.
Jayadevappa R; Chhatre S; Malkowicz SB; Parikh RB; Guzzo T; Wein AJ
JAMA Netw Open; 2019 Jul; 2(7):e196562. PubMed ID: 31268539
[TBL] [Abstract][Full Text] [Related]
13. Risk of Alzheimer's Disease Among Senior Medicare Beneficiaries Treated With Androgen Deprivation Therapy for Prostate Cancer.
Baik SH; Kury FSP; McDonald CJ
J Clin Oncol; 2017 Oct; 35(30):3401-3409. PubMed ID: 28841388
[TBL] [Abstract][Full Text] [Related]
14. Different androgen deprivation therapies might have a differential impact on cognition - An analysis from a population-based study using time-dependent exposure model.
Hong JH; Huang CY; Chang CH; Muo CH; Jaw FS; Lu YC; Chung CJ
Cancer Epidemiol; 2020 Feb; 64():101657. PubMed ID: 31918180
[TBL] [Abstract][Full Text] [Related]
15. Statin reduces the risk of dementia in diabetic patients receiving androgen deprivation therapy for prostate cancer.
Liu JM; Chen TH; Chuang HC; Wu CT; Hsu RJ
Prostate Cancer Prostatic Dis; 2019 May; 22(2):276-283. PubMed ID: 30337635
[TBL] [Abstract][Full Text] [Related]
16. Androgen deprivation therapy for prostate cancer and the risk of hematologic disorders.
Liu JM; Liu YP; Chuang HC; Wu CT; Su YL; Hsu RJ
PLoS One; 2020; 15(2):e0229263. PubMed ID: 32074125
[TBL] [Abstract][Full Text] [Related]
17. Androgen deprivation therapy for prostate cancer and dementia risk: a systematic review and meta-analysis.
Nead KT; Sinha S; Nguyen PL
Prostate Cancer Prostatic Dis; 2017 Sep; 20(3):259-264. PubMed ID: 28349979
[TBL] [Abstract][Full Text] [Related]
18. Risk of dementia and Parkinson's disease in patients treated with androgen deprivation therapy using gonadotropin-releasing hormone agonist for prostate cancer: A nationwide population-based cohort study.
Shim M; Bang WJ; Oh CY; Lee YS; Jeon SS; Ahn H; Ju YS; Cho JS
PLoS One; 2020; 15(12):e0244660. PubMed ID: 33378392
[TBL] [Abstract][Full Text] [Related]
19. Risk of dementia following androgen deprivation therapy for treatment of prostate cancer.
Krasnova A; Epstein M; Marchese M; Dickerman BA; Cole AP; Lipsitz SR; Nguyen PL; Kibel AS; Choueiri TK; Basaria S; Mucci LA; Sun M; Trinh QD
Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):410-418. PubMed ID: 31784699
[TBL] [Abstract][Full Text] [Related]
20. Subsequent risk of acute urinary retention and androgen deprivation therapy in patients with prostate cancer: A population-based retrospective cohort study.
Yang TK; Wu CC; Chang CH; Muo CH; Huang CY; Chung CJ
Medicine (Baltimore); 2020 Feb; 99(7):e18842. PubMed ID: 32049786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]